- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02074943
Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia
Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia: A Double-Blind, Randomized, Placebo Controlled Trial
Study Overview
Detailed Description
Platelet rich plasma (PRP) is made from your own blood by taking a sample of venous blood, placing it in a special tube, and spinning the blood in a centrifuge which is a piece of equipment used to separate the components of blood. Blood is made of red blood cells, white blood cells and platelets, while plasma, the liquid component is predominantly water but also contains clotting factors, proteins, and glucose. Platelets are small, disk shaped clear cell fragments which are a natural source of growth factors. They circulate in the blood and are involved in hemostasis which is a process which causes bleeding to stop, leading to the formation of blood clots. So-called "Platelet-rich plasma" represents the patient's own plasma that has been mechanically centrifuged to increase the concentration of platelets compared to the whole blood. The basic idea behind PRP injection is to deliver high concentrations of growth factors to the scalp, with the hope of stimulating hair regrowth.
PRP is an innovative therapy and has been used since 1987 to help promote healing in orthopedic surgery, dental surgery and dermatology. Recently, there have been reports supporting the use of PRP in the treatment of hair loss.
Androgenetic alopecia (AGA) is the most common cause of hair loss. It has very limited treatment modalities which includes minoxidil, 5-alpha reductase inhibitors and hair transplantation. Each option has its own side effects range from hypertrichosis which is excessive hair growth, possible birth defects if given to women of child bearing age, decreased libido and the possibility of prolonged impotence.
To our best knowledge, there are no double blind, randomized, placebo-controlled trials evaluating the efficacy and safety of PRP injection in treating AGA. A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. The investigators plan to conduct a clinical trial to assess the effects and safety of PRP on AGA. The investigators also plan to identify the presence of various growth factors in PRP and their correlations in hair regrowth.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jerry Shapiro, MD
- Phone Number: 604-875-5151
- Email: Jerry.Shapiro@vch.ca
Study Locations
-
-
-
Vancouver, Canada, V5Z 4E8
- Recruiting
- The Skin Care Center, Vancouver General Hospital
-
Contact:
- Jerry Shapiro, MD
- Phone Number: 604-875-5151
- Email: Jerry.Shapiro@vch.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females in good general health, ages 18-70.
- Patients with mild to moderate AGA (Ludwig alopecia score I and II, and the Hamilton-Norwood score 1 to 4).
Exclusion Criteria:
- Patients who received treatments for AGA within the last 3 months.
- Patients who have active or history of malignancies.
- Patients with platelets disorders, anemia and or bleeding disorders.
- Women who are pregnant or breast-feeding.
- Un-cooperative patients or patients who are unable to understand the protocol or give informed consent.
- Patients who are known to be HIV, hepatitis B or C positive or otherwise immunocompromised.
- Subjects who have active skin disease or skin infection at the intended treatment area.
- Patients on non-steroidal anti-inflammatory medications.
- Patients with a propensity for keloids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRP/Saline
Same patient will be injected with PRP and normal saline.
Each one will be inject on half head.
|
PRP will be inject to half head.
The other half will be injected with normal saline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The degree of hair regrowth based on the hair regrowth score (RGS) for each side of scalp.
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in hair count and caliber. Changes in hair count and caliber
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jerry Shapiro, MD, Professor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H13-03126
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Androgenetic Alopecia
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Suzhou Kintor Pharmaceutical Inc,Completed
-
King Edward Medical UniversityCompletedCombination of SVF and PRP for Androgenetic AlopeciaPakistan
-
Chong Kun Dang PharmaceuticalRecruitingAndrogenetic AlopeciaKorea, Republic of
-
EMSRecruitingAndrogenetic AlopeciaBrazil
-
Services Hospital, LahoreActive, not recruitingAndrogenetic AlopeciaPakistan
-
Hope Medicine (Nanjing) Co., LtdCompleted
-
Indonesia UniversityActive, not recruitingAndrogenetic AlopeciaIndonesia
-
Cairo UniversityCompleted
-
University Hospitals Cleveland Medical CenterUniversity of California, San Francisco; Kaiser PermanenteCompleted
Clinical Trials on PRP
-
Sun Yat-sen UniversityUnknownSevere Non-proliferative Diabetic RetinopathyChina
-
Ankara Universitesi TeknokentCompleted
-
National Defense Medical Center, TaiwanTri-Service General HospitalRecruitingAnkle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeTaiwan
-
Postgraduate Institute of Dental Sciences RohtakUnknownPeriapical Lesions
-
Cairo UniversityRecruiting
-
University of Colorado, DenverTerumo BCTCompletedOsteochondritis DissecansUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingDry Age-related Macular DegenerationItaly
-
Yantai Yuhuangding HospitalRecruitingKnee OsteoarthritisChina
-
Yantai Yuhuangding HospitalTerminated
-
Hospital for Special Surgery, New YorkRecruiting